Benefits Outweigh Risks for Weight Loss Drug Mysimba
The European Medicines Agency (EMA) has concluded a review of the weight loss drug naltrexone/bupropion (Mysimba), which was prompted by concerns about potential long-term cardiovascular risks. The scientific assessment of the EMA’s Committee for Medicinal Products for Human Use (CHMP) was that available data suggested that the benefits of its authorized indication “continue to outweigh …
Read More
0
